WO2012077932A3 - Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant - Google Patents
Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant Download PDFInfo
- Publication number
- WO2012077932A3 WO2012077932A3 PCT/KR2011/009224 KR2011009224W WO2012077932A3 WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3 KR 2011009224 W KR2011009224 W KR 2011009224W WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridine derivative
- same
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Cette invention concerne un nouveau dérivé de pyrazole pyridine ou des sels de qualité pharmaceutique de celui-ci, leur procédé de production, et une composition pharmaceutique les contenant. Le nouveau dérivé de pyrazole pyridine selon la présente invention inhibe la GSK-3β, et peut être efficacement utilisé pour prévenir ou traiter les troubles liés à la démence, à la maladie d'Alzheimer, à la maladie de Parkinson, au parkinsonisme variante démence frontotemporale, au complexe Parkinson-démence de Guam, à la démence due au VIH, ou aux pathologies liées à des enchevêtrements neurofibrillaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100124391A KR20120063283A (ko) | 2010-12-07 | 2010-12-07 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
KR10-2010-0124391 | 2010-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012077932A2 WO2012077932A2 (fr) | 2012-06-14 |
WO2012077932A3 true WO2012077932A3 (fr) | 2012-09-07 |
Family
ID=46207575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/009224 WO2012077932A2 (fr) | 2010-12-07 | 2011-11-30 | Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20120063283A (fr) |
WO (1) | WO2012077932A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2487159A1 (fr) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | Inhibiteurs du RORgammaT |
WO2014026327A1 (fr) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations |
WO2014026330A1 (fr) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés 3-aminocycloalkyles en tant qu'inhibiteurs de rorgammat et leurs utilisations |
CN105712992B (zh) * | 2012-09-29 | 2018-10-26 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
SI3152199T1 (sl) | 2014-06-03 | 2018-12-31 | Idorsia Pharmaceuticals Ltd | Pirazolne spojine in njihova uporaba kot blokatorji kalcijevega kanala tipa T |
US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
JP2018510135A (ja) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害剤としての置換ピラゾール化合物及びその使用 |
US10584121B2 (en) | 2015-10-27 | 2020-03-10 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof |
EP3368516B1 (fr) | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | Composés pyrazoles bicycliques substitués en tant qu'inhibiteurs de rorgammat et leurs utilisations |
AU2016344115A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
CN111995589B (zh) * | 2015-11-10 | 2023-12-05 | 国立大学法人九州大学 | 2,5-二氰基-3,6-二卤代吡嗪的制造方法 |
KR102296653B1 (ko) | 2016-12-16 | 2021-09-01 | 이도르시아 파마슈티컬스 리미티드 | T-유형 칼슘 채널 차단제를 포함하는 약학 조합물 |
TWI808960B (zh) | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
WO2022015938A1 (fr) * | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
JP2024502472A (ja) * | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
CA3223223A1 (fr) | 2021-06-28 | 2023-01-05 | Blueprint Medicines Corporation | Inhibiteurs de cdk2 |
CN118126038B (zh) * | 2024-05-08 | 2024-07-12 | 烟台大学 | 吡唑并吡啶类衍生物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045949A1 (fr) * | 2001-11-26 | 2003-06-05 | Smithkline Beecham P.L.C. | Derives de pyrazolopyridine |
WO2003068773A1 (fr) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Derives de pyrazolopyridine |
WO2004013140A1 (fr) * | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Compositions pyrazole convenant comme inhibiteurs de gsk-3 |
WO2009145814A2 (fr) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases |
WO2010104306A2 (fr) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme |
-
2010
- 2010-12-07 KR KR1020100124391A patent/KR20120063283A/ko not_active Application Discontinuation
-
2011
- 2011-11-30 WO PCT/KR2011/009224 patent/WO2012077932A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045949A1 (fr) * | 2001-11-26 | 2003-06-05 | Smithkline Beecham P.L.C. | Derives de pyrazolopyridine |
WO2003068773A1 (fr) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Derives de pyrazolopyridine |
WO2004013140A1 (fr) * | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Compositions pyrazole convenant comme inhibiteurs de gsk-3 |
WO2009145814A2 (fr) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases |
WO2010104306A2 (fr) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme |
Also Published As
Publication number | Publication date |
---|---|
WO2012077932A2 (fr) | 2012-06-14 |
KR20120063283A (ko) | 2012-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012077932A3 (fr) | Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant | |
WO2009127642A3 (fr) | Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives | |
IN2012DN02968A (fr) | ||
WO2017132432A8 (fr) | Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma | |
NZ598137A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
WO2012080729A3 (fr) | Inhibiteurs de caséine kinase 1δ (ck1δ) | |
IN2014DN03206A (fr) | ||
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MX2009010407A (es) | Derivados fluorados de deferiprona. | |
WO2014045162A8 (fr) | Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués | |
MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
ZA201306833B (en) | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease | |
MX2015000334A (es) | Derivado de benzodioxol y metodo de preparacion y uso del mismo. | |
MX2015003732A (es) | Tratamiento de enfermedad de alzheimer leve y moderada. | |
MX2015016539A (es) | 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol -3-il)bencenosulfonamida como modulador de nachr alfa 7. | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
WO2011089576A3 (fr) | Nouvelles compositions pour réduire la production de ass 42 et leur utilisation dans le traitement de la maladie d'alzheimer (ad) | |
WO2011094434A3 (fr) | Dérivés de 7-azoniabicyclo[2.2.1]heptane, procédés de production, et utilisation pharmaceutiques de ceux-ci | |
MX2012012410A (es) | Agente terapeutico y agente preventivo para enfermedad de alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11847604 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11847604 Country of ref document: EP Kind code of ref document: A2 |